Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Inclusion * Pathologically confirmed invasive breast cancer with ER \< 10%, PR \< 10%, by IHC, HER2 1+ or 0 or FISH negative * Measurable (\>= 1 cm) or assessable disease detectable by imagining or physical exam * Patients with bone only disease have measurable lesions on x-ray, MRI, or CT scan * Only one or no prior therapy for metastatic or recurrent breast cancer is allowed * Prior chemotherapy or radiation therapy is permitted but at least 2 weeks should elapse prior to study enrollment * Prior therapy with bevacizumab is permitted but at least 2 weeks should elapse prior to study enrollment * Prior therapy with bevacizumab is permitted but at least 28 days should elapse from the last bevacizumab treatment prior to study enrollment * ECOG PS or 0-1 * Signed protocol specific informed consent prior to registration * Life expectancy greater than 3 months * Please contact study investigator and/or consult the protocol document for specific laboratory criteria * Tissue block available from primary breast cancer * Premenopausal women must have a negative serum or urine pregnancy test prior to starting on study treatment (post-menopausal is defined as \> 6 months of amenorrhea prior hysterectomy) Exclusion * More than or equal to 2 prior regimens for metastatic breast cancer * Leptomeningeal disease * Brain metastasis except for a solitary lesion that was resected or treated with gamma knife with no residual disease on CT or MRI or received whole brain RT and f/u MRI was normal with no residual neurologic deficit * History of interstitial lung disease (ie pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan * History of irreversible neuropathy * Another malignancy other than carcinoma in situ of the cervix or skin cancer * Active uncontrolled bacterial viral or fungal infection * Active pregnancy or breast feeding * Patients with pre-existing neuropathy \>= grade 2 * History of myocardial infarction, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia * Patients with previous history of CTCAE grade \>= 3 hypersensitivity to paclitaxel or Cremophor EL are not eligible